Nanoviricides (NNVC) Assets Average (2011 - 2026)
Nanoviricides (NNVC) posted Assets Average of $11.2 million for Q1 2026, up 9.03% sequentially from $10.3 million in Q4 2025, and up 4.09% YoY from $10.8 million in Q1 2025.
Nanoviricides (NNVC) Assets Average (2011 - 2026) Analysis & Trends
Nanoviricides has reported Assets Average for 16 years, with the latest figure at $11.2 million in Q1 2026.
- Quarterly Assets Average rose 4.09% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 4.09% YoY) and the FY2025 annual result came in at $10.8 million, down 27.17% from the prior year.
- Assets Average advanced to $11.2 million in Q1 2026 per NNVC's latest filing, from $10.3 million in the prior quarter.
- Over five years, Assets Average peaked at $26.0 million in Q1 2022 and troughed at $8.6 million in Q3 2025.
- A 5-year average of $15.3 million and a median of $12.4 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2026: Assets Average slumped 36.09% in 2024, then advanced 4.09% in 2026.
- Over 5 years, Assets Average stood at $21.2 million in 2022, then slumped by 32.06% to $14.4 million in 2023, then slipped by 19.11% to $11.7 million in 2024, then decreased by 11.52% to $10.3 million in 2025, then grew by 9.03% to $11.2 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $11.2 million, $10.3 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | 11.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.24 Mn |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 8.59 Mn |
| Jun 30, 2025 | 9.43 Mn |
| Mar 31, 2025 | 10.80 Mn |
| Dec 31, 2024 | 11.66 Mn |
| Sep 30, 2024 | 12.28 Mn |
| Jun 30, 2024 | 12.14 Mn |
| Mar 31, 2024 | 12.43 Mn |
| Dec 31, 2023 | 14.41 Mn |
| Sep 30, 2023 | 16.16 Mn |
| Jun 30, 2023 | 17.74 Mn |
| Mar 31, 2023 | 19.46 Mn |
| Dec 31, 2022 | 21.21 Mn |
| Sep 30, 2022 | 22.79 Mn |
| Jun 30, 2022 | 24.32 Mn |
| Mar 31, 2022 | 25.98 Mn |
| Dec 31, 2021 | 27.99 Mn |
| Sep 30, 2021 | 29.72 Mn |
| Jun 30, 2021 | 31.51 Mn |